EpiEndo Pharmaceuticals are proud to announce our new partnership with Recipharm, a Swedish Contract Development and Manufacturing Organisation (CDMO). EpiEndo and Recipharm will be collaborating in the synthesis of our novel compound, which will be led by Fredrik Lehman, our CMC Director and General Manager at Recipharm.

EpiEndo Pharmaceuticals has been granted a 2 year grant by RANNÍS - The Icelandic Centre for Research - for compound research and patent applications, as well as to initiate studies that will be the foundations of clinical testing and development of novel drugs for the treatment of airway diseases.

REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.